Overview

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

Status:
Completed
Trial end date:
2019-09-29
Target enrollment:
Participant gender:
Summary
This will be a Phase I, 2-part, open-label, non-randomized study to investigate the safety, tolerability, and pharmacokinetics (PK) of a multiple-dosing regimen of risdiplam (Part 1) and the effect of risdiplam on the PK of midazolam (Part 2) following oral administration in healthy adult male and female participants.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Midazolam
Risdiplam